Possible protective effects of tirzepatide on polycystic ovary syndrome in female rat model induced by testosterone propionate in comparison to metformin
Abstract
Polycystic ovary syndrome (PCOS) is a complex endocrine-metabolic disorder characterized by hyperandrogenism, ovulatory dysfunction, insulin resistance, and chronic inflammation resulting in reproductive and metabolic complications. Traditional metformin therapy improves insulin sensitivity, while newer dual incretin agonists, such as tirzepatide, may offer broader metabolic and ovarian protection. The objective of this study is to investigate whether tirzepatide could alter hormonal parameters, metabolism, inflammation, and histopathology of a testosterone propionate-induced PCOS rat model compared with metformin. Thirty prepubertal female Wistar rats were divided into five groups (n = 6). PCOS was induced by testosterone propionate (10 mg/kg/day, subcutaneous) for 30 days. Rats were then given tirzepatide (0.88 and 1.32 mg/kg/week, subcutaneous), metformin (300 mg/kg/day, oral), or vehicle for 14 days. Serum reproductive hormones, lipid profile, fasting glucose, insulin, and HOMA-IR were assessed. The mRNA expression of ovarian Tnf-α and Il-6 was determined by RT qPCR, western blot analysis of caspase 3 protein, and histopathological assessment of ovarian morphology. Testosterone propionate resulted in pronounced hyperandrogenism and an increased LH/FSH ratio, dyslipidemia, hyperglycemia and insulin resistance, and ovarian inflammation and apoptosis. Tirzepatide induced significant improvements in estradiol, testosterone, LH, FSH, and LH/FSH ratio. A greater reduction in…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.